Long-term Parkinson's disease - Time for optimism

被引:4
|
作者
Yust-Katz, Shlomit [1 ,2 ]
Sthneer, Sonia [1 ,2 ]
Melamed, Eldad [1 ,2 ]
Djaldetti, Ruth [1 ,2 ]
机构
[1] Rabin Med Ctr, Dept Neurol, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
关键词
Parkinson's disease; long term; levodopa; Hoehn and Yahr stage;
D O I
10.1016/j.biopha.2007.12.014
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Data on the natural long-term course of Parkinson's disease (PD) remain sparse. The aim of this study was to describe the evolution of the functional disability and the response to dopaminergic therapy in patients with PD for many years. The files of 47 patients who had been diagnosed with PD more than 13 years previously were reviewed. Mean age at disease onset was 47 9 years, and mean disease duration was 23.5 +/- 9.8 years. Levodopa treatment was initially effective in 95% of the patients but the response decreased with time. At the end of the follow-up period, end-stage disease, i.e. Hoehn and Yahr (H&Y) stage 5 was documented in 45% of the patients. In patients with response fluctuations H&Y stage was graded 5 in 53% of patients in the "off" period and in 27% in the "on" period. In patients without response fluctuations H&Y stage was graded 5 in 23% of patients. Two patients had stage 2 disease (minimal disability). In conclusion, PD has a chronic progressive course, although most patients do not reach end-stage disease. The effect of L-dopa treatment decreases over time, but is not lost completely. (c) 2008 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:233 / 235
页数:3
相关论文
共 50 条
  • [1] Long-term course of Parkinson's disease
    Ebersbach, G.
    NERVENHEILKUNDE, 2010, 29 (06) : 345 - 350
  • [2] Long-Term Efficacy of Rasagiline in Early Parkinson's Disease
    Lew, Mark F.
    Hauser, Robert A.
    Hurtig, Howard I.
    Ondo, William G.
    Wojcieszek, Joanne
    Goren, Tamar
    Fitzer-Attas, Cheryl J.
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2010, 120 (06) : 404 - 408
  • [3] Duodenal levodopa infusion in Parkinson's disease - long-term experience
    Nilsson, D
    Nyholm, D
    Aquilonius, SM
    ACTA NEUROLOGICA SCANDINAVICA, 2001, 104 (06): : 343 - 348
  • [4] Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease
    Cattaneo, Carlo
    Mueller, Thomas
    Bonizzoni, Erminio
    Lazzeri, Gabriele
    Kottakis, Ioannis
    Keywood, Charlotte
    JOURNAL OF PARKINSONS DISEASE, 2017, 7 (04) : 629 - 634
  • [5] Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain
    Cattaneo, Carlo
    Kulisevsky, Jaime
    Tubazio, Viviana
    Castellani, Paola
    ADVANCES IN THERAPY, 2018, 35 (04) : 515 - 522
  • [6] Long-term results with cisapride in Parkinson's disease
    Jost, WH
    Schimrigk, K
    MOVEMENT DISORDERS, 1997, 12 (03) : 423 - 425
  • [7] Long-term monitoring of gait in Parkinson's disease
    Moore, Steven T.
    MacDougall, Hamish G.
    Gracies, Jean-Michel
    Cohen, Helen S.
    Ondo, William G.
    GAIT & POSTURE, 2007, 26 (02) : 200 - 207
  • [8] Long-term medical treatment for Parkinson’s disease
    John M. Bertoni
    Jose-Luis Prendes
    Pamela Sprenkle
    Current Treatment Options in Neurology, 2001, 3 (6) : 495 - 506
  • [9] Long-Term Outcomes of Genetic Parkinson's Disease
    Aasly, Jan O.
    JOURNAL OF MOVEMENT DISORDERS, 2020, 13 (02) : 81 - 96
  • [10] Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease
    Nyholm, D.
    Klangemo, K.
    Johansson, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 (08) : 1079 - 1085